Day: April 8, 2021

Organizuotų kelionių lyderiui Baltijos šalyse „Novaturas“ š. m. balandžio 2 dieną pasirašius 10 milijonų vertės investavimo sutartį su Valstybės investicijų valdymo agentūra, nuo šiandien įsigalioja su AB „Luminor“ banku susitartos palankesnes paskolų grąžinimo sąlygos:AB „Luminor“ bankas sumažina paskolų palūkanas ir pratęsia „Novaturui“ suteiktos ilgalaikės 5,3 mln. eurų paskolos galutinį grąžinimo terminą iki 2023 m. pabaigos, pakeičiant gražinimo grafiką bei jį geriau suderinant su planuojamais bendrovės pinigų srautais. AB „Luminor“ bankas atsisako reikalavimo bendrovei laikyti įšaldytas lėšas, kurių vertė siekia 2,1 mln. Eurų, nukreipiant jas paskolų gražinimui.Tuo pačiu, susitarimuose iš anksto aptartos ir numatytos palankios sąlygos garantijų limito pratęsimui jau ir 2022 metų sezonui. Apie įmonę AB „Novaturo“ grupė yra didžiausias...

Dovre Group Plc                   Managers’ Transactions               April 8, 2021 at 7.30 pm Dovre Group Plc: Managers’ Transactions – Jensen Arve (receipt of a share-based incentive or remuneration) Dovre Group Plc – Managers’ Transactions ____________________________________________ Person subject to the notification requirementName: Jensen, ArvePosition: Chief Executive Officer Issuer: Dovre Group PlcLEI: 7437000NA1I6Y1OQWL24 Notification type: INITIAL NOTIFICATIONReference number: 7437000NA1I6Y1OQWL24_20210408181738_2 ____________________________________________ Transaction date: 2021-04-08Venue not applicableInstrument type: SHAREISIN: FI0009008098Nature of the transaction: RECEIPT OF A SHARE-BASED INCENTIVE OR REMUNERATION Transaction details (1): Volume: 494,120 Unit price:  EUR Aggregated transactions (1):...

Dovre Group Oyj                        Johdon liiketoimet                  8.4.2021 klo 19.30 Dovre Group Oyj: Johdon liiketoimet – Jensen (osakepalkkion vastaanottaminen) Dovre Group Oyj – Johdon liiketoimet ____________________________________________ IlmoitusvelvollinenNimi: Jensen, ArveAsema: Toimitusjohtaja Liikkeeseenlaskija: Dovre Group OyjLEI: 7437000NA1I6Y1OQWL24 Ilmoituksen luonne: ENSIMMÄINEN ILMOITUSViitenumero: 7437000NA1I6Y1OQWL24_20210408181738_2 ____________________________________________ Liiketoimen päivämäärä: 2021-04-08Kauppapaikka ei sovelluInstrumenttityyppi: OSAKEISIN: FI0009008098Liiketoimen luonne: OSAKEPALKKION VASTAANOTTAMINEN Liiketoimien yksityiskohtaiset tiedot (1): Volyymi: 494 120 Yksikköhinta:  EUR Liiketoimien yhdistetyt tiedot (1): Volyymi: 494 120 Keskihinta:  EUR Lisätiedot: Dovre Group OyjSirpa...

Confirming the effect of AsiDNA™ on resistance to KRAS inhibitors Introducing OX400, a new generation of PARP interfering cancer drug candidatesPARIS, April 08, 2021 (GLOBE NEWSWIRE) — Onxeo S.A. (Euronext Growth Paris: ALONX, First North Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), today announced the presentation of preclinical data confirming the differentiated antitumoral properties of the drug candidates generated by platON™, its patent-protected platform of decoy-agonists of the DNA Damage Response, in e-poster sessions during the American Association for Cancer Research (AACR 2021) virtual annual meeting on April 10, 2021. The first e-poster supports the ability of AsiDNA™, the Company’s...

SOUTH SAN FRANCISCO, Calif., April 08, 2021 (GLOBE NEWSWIRE) — Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 20th Annual Needham Virtual Healthcare Conference on Tuesday, April 13, 2021 at 12:45 pm PT / 3:45 pm ET. Tricida will provide a company overview, business update and progress on the company’s key initiatives. A live webcast of the presentation will be accessible on the Tricida website at IR.Tricida.com. An archive of the webcast will be available for 90 days following the presentation. About Tricida Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with CKD. Tricida is currently conducting a renal outcomes clinical...

Rueil Malmaison, 8 April 2021 VINCI Shareholders’ General Meeting of 8 April 2021Approval of all resolutions Dividend in respect of 2020: €2.04 per share, to be paid in cash on 22 April 2021 Renewal of the term of office as Director of Mrs Yannick Assouad, Lead Director, and of Mrs Graziella Gavezotti Shareholders’ support for the Group’s environmental ambition, a first in FranceVINCI’s Combined Shareholders General Meeting, chaired by Xavier Huillard, Chairman and Chief Executive Officer, was held on 8 April 2021 at the company’s head office in Rueil Malmaison. It took place behind closed doors due to the Covid-19 epidemic. With a 65.66% quorum, the meeting approved all the resolutions submitted, of which:the parent company and consolidated financial statements for the fiscal year ended 31 December 2020; a dividend of €2.04 per...

Rueil-Malmaison, le 8 avril 2021 Assemblée générale des actionnaires de VINCI du 8 avril 2021Approbation de l’ensemble des résolutions Dividende au titre de l’exercice 2020 : 2,04 euros par action, payable en numéraire le 22 avril 2021 Renouvellement des mandats d’administrateur de Mme Yannick Assouad, administrateur référent, et de Mme Graziella Gavezotti Adhésion des actionnaires à l’ambition environnementale du Groupe, une première en FranceL’assemblée générale mixte des actionnaires de VINCI s’est réunie le 8 avril 2021 au siège social de la société à Rueil-Malmaison, sous la présidence de Xavier Huillard, président-directeur général. Elle s’est tenue à huis clos en raison de l’épidémie de Covid-19. Avec un quorum de 65,66 %, l’assemblée générale a approuvé l’ensemble des résolutions qui lui étaient soumises, dont :les...

8 April 2021 – Delta Drone International (ASX:DLT) (Delta Drone or the Company) is pleased to announce it has appointed Mr Christian Viguié and Mr Nicolas Clerc to the Board of Directors as non-executive directors with immediate effect. Christian is Chairman and CEO of Delta Drone SA, Delta Drone’s majority shareholder. A graduate of IEP Paris, Christian worked as a financial analyst before forming several financial reporting companies. He also served as Director General of the Unilog Group from 1998 to 2006, where he was responsible for relationships with the finance community. Nicolas is Group CFO of Delta Drone SA. Nicolas has an Advanced Degree in Accounting and Management and 20 years’ experience in accounting and audit firms including PriceWaterhouseCoopers and TEOREM. He joined the Delta Drone group in September 2017 as Group...

Communiqué ASX 8 avril 2021 à 18h – Delta Drone International (ASX : DLT) a le plaisir d’annoncer la nomination de MM. Christian Viguié et Nicolas Clerc au Conseil d’Administration en tant qu’administrateurs non exécutifs avec effet immédiat. Christian est Président-directeur général de Delta Drone SA, actionnaire majoritaire de Delta Drone International. Diplômé de l’IEP Paris, Christian a travaillé comme analyste financier avant de créer plusieurs sociétés de conseil et d’information financière. Il a également été directeur général du groupe Unilog de 1998 à 2006, où il était responsable des relations avec la communauté financière. Nicolas est Directeur financier de Delta Drone SA. Diplômé d’études supérieures en comptabilité et gestion, Nicolas jouit de 20 ans d’expérience dans des cabinets...

Disclosure of Share Capital and Voting Rights Outstandingas of March 31, 2021 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers) Charenton-le-Pont, France (April 8, 2021 – 6:00 pm) – As of March 31, 2021, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks down as indicated below.  March 31, 2021Shares outstanding          439,022,4511Number of real voting rights (excluding treasury shares) 437,816,742Theoretical number of voting rights (including treasury shares) 439,022,451It is to be noted that voting rights are capped at 31%, applicable to any shareholder, in accordance with a formula...